Full Press Release Details
Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease.
BIIB
Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease
Key Takeaway: Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis